Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $78.3 million.

  • Prestige Consumer Healthcare's Cash from Operations rose 2027.32% to $78.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $276.6 million, marking a year-over-year increase of 781.84%. This contributed to the annual value of $251.5 million for FY2025, which is 104.01% up from last year.
  • As of Q4 2025, Prestige Consumer Healthcare's Cash from Operations stood at $78.3 million, which was up 2027.32% from $57.5 million recorded in Q3 2025.
  • Prestige Consumer Healthcare's Cash from Operations' 5-year high stood at $79.0 million during Q2 2025, with a 5-year trough of $48.1 million in Q2 2023.
  • Its 5-year average for Cash from Operations is $63.2 million, with a median of $62.2 million in 2023.
  • Over the last 5 years, Prestige Consumer Healthcare's Cash from Operations had its largest YoY gain of 4424.75% in 2025, and its largest YoY loss of 1764.18% in 2025.
  • Quarter analysis of 5 years shows Prestige Consumer Healthcare's Cash from Operations stood at $66.3 million in 2021, then fell by 17.13% to $54.9 million in 2022, then surged by 30.09% to $71.5 million in 2023, then dropped by 8.93% to $65.1 million in 2024, then increased by 20.27% to $78.3 million in 2025.
  • Its Cash from Operations stands at $78.3 million for Q4 2025, versus $57.5 million for Q3 2025 and $79.0 million for Q2 2025.